Categories Earnings, Health Care

Sarepta Therapeutics (SRPT): Q4 2019 Earnings Snapshot

Earnings Update by AlphaStreet

—  Sarepta Therapeutics, Inc.  (NASDAQ: SRPT) reported a loss of $1.57 per share in the fourth quarter of 2019, vs $1.86 per share loss expected.

— Q4 revenue rose 19% to $100.1 million, vs. $98.8 million expected. Results were helped by an increase in demand for EXONDYS 51 in the U.S.

— Appointed biotech executive John C. Martin to Board of Directors. He is a former Gilead CEO.

— SRPT shares ended Wednesday’s regular trading session down 1.14%. 

Listen to on-demand earnings calls and hear how management responds to analysts’ questions

Most Popular

V Earnings: Key quarterly highlights from Visa’s Q1 2023 financial results

Visa Inc. (NYSE: V) reported first quarter 2023 earnings results today. Net revenues grew 12% year-over-year to $7.9 billion. GAAP net income rose 6% to $4.2 billion while EPS grew

Earnings: Highlights of Intel’s (INTC) Q4 2022 financial results

Intel Corporation (NASDAQ: INTC) Thursday reported a decline in adjusted earnings and revenues for the fourth quarter. The semiconductor giant also provided guidance for the first quarter of 2023. Fourth-quarter

McCormick (MKC) expects to drive sales growth in 2023 through pricing actions and cost savings

Shares of McCormick & Company Inc. (NYSE: MKC) were down over 5% on Thursday after the company missed expectations on its fourth quarter 2022 results and provided a lower-than-expected earnings

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top